Progenics Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PROGENICS PHARMS INC, and when can generic versions of PROGENICS PHARMS INC drugs launch?
PROGENICS PHARMS INC has two approved drugs.
There are four US patents protecting PROGENICS PHARMS INC drugs.
There are seventy-three patent family members on PROGENICS PHARMS INC drugs in twenty-two countries and one supplementary protection certificate in one country.
Summary for Progenics Pharms Inc
| International Patents: | 73 |
| US Patents: | 4 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Progenics Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | 8,778,305 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | 9,861,713 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | 8,487,129 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Progenics Pharms Inc | AZEDRA | iobenguane i-131 | SOLUTION;INTRAVENOUS | 209607-001 | Jul 30, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | 10,947,197 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Progenics Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 3222615 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2008058192 | ⤷ Try a Trial |
| European Patent Office | 2942065 | ⤷ Try a Trial |
| Spain | 2847275 | ⤷ Try a Trial |
| Singapore | 11201810916W | ⤷ Try a Trial |
| Australia | 2007316391 | ⤷ Try a Trial |
| South Korea | 102558962 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Progenics Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2318366 | 301250 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PIFLUFOLASTAT (18F) OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1746 20230725 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
